# A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation

> **NCT06599502** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 17 (actual)

## Conditions studied

- Advanced Solid Tumours
- Non-Small Cell Lung Cancer (NSCLC)
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Colorectal Cancer (CRC)

## Interventions

- **DRUG:** AZD0022
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT06599502
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-10-18
- **Primary completion:** 2025-10-20
- **Final completion:** 2026-01-29
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** The decision to cease enrolment and proceed with the early termination of the ALAFOSS 01 (D7080C00001) study was based on strategic company portfolio prioritization.
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06599502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06599502, "A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06599502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*